Business Context and Reporting Period
This Form 8-K is a current report filed by Aeglea BioTherapeutics, Inc. (not Spyre Therapeutics, Inc.) on June 8, 2018, regarding events occurring on June 7, 2018. The filing details the results of the Company's 2018 Annual Meeting of Stockholders. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results rather than financial performance.
Material Changes and Voting Results
Three proposals were submitted to and adopted by the stockholders at the Annual Meeting:
- Election of Directors: Two Class II directors were elected to three-year terms expiring in 2021:
- Russell Cox: 11,603,911 shares For; 425,239 shares Withheld.
- Ivana Magovcevic-Liebisch, Ph.D.: 12,014,021 shares For; 15,129 shares Withheld.
- Ratification of Auditors: PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
- Vote Count: 15,090,949 shares For; 10,094 shares Against; 43 shares Abstaining.
- Amendment to 2016 Employee Stock Purchase Plan: Approved an amendment to provide for an automatic annual increase in shares reserved for issuance on January 1 of each year. The increase is set at 1.0% of issued and outstanding shares on the preceding December 31, or a lesser amount approved by the Board.
- Vote Count: 10,387,850 shares For; 1,620,743 shares Against; 20,557 shares Abstaining.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the reporting of voting outcomes.
Important Facts for Investors to Verify
- Confirm the correct registrant name is Aeglea BioTherapeutics, Inc., as the input metadata referenced Spyre Therapeutics, Inc.
- Verify the total number of shares outstanding to contextualize the voting percentages, as the filing lists absolute share counts but not total outstanding shares.
- Review the specific terms of the 2016 Employee Stock Purchase Plan amendment to understand the impact on future share dilution.
- Check subsequent filings for the Company's financial performance, as this 8-K contains no financial data.